Navigation Links
ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
Date:4/23/2009

th pegylated interferon and ribavirin. The actual timing for the initiation of Phase II studies may depend on a number of factors, including FDA review timelines, the timing of any potential transaction around ANA598 or ANA773, available cash resources and funding activities, and the engagement of clinical sites.

14 Day Healthy Volunteer Study

Anadys recently completed dosing healthy volunteers in a 14-day study conducted to extend the safety and pharmacokinetic profile of ANA598. Thirty subjects participated in the study, with eight subjects receiving ANA598 and two subjects receiving placebo at each dose level (400 mg once-daily, 800 mg once-daily and 600 mg bid). Subjects received ANA598 or placebo on day one followed by pharmacokinetic assessment over days two and three and received subsequent doses consecutively on days four through fourteen. Preliminary results from the study indicate that ANA598 was generally well-tolerated in all cohorts with no serious adverse events, although three subjects receiving ANA598 (two in the 800 mg once-daily cohort and one in the 600 mg bid cohort) developed grade 2 rash and discontinued treatment after either six or seven days of consecutive dosing. There were no other instances of rash in this or any other study of ANA598. Data receipt and analysis from this study is continuing, and the Company expects to present the results at a clinical conference later this year. The Company believes the results of this study, combined with the results of the Phase Ib study in HCV patients, contribute to the attractive profile of ANA598 as an antiviral likely to be active in long-term studies in combination with pegylated interferon and ribavirin, and help position the program to be ready for Phase II in mid-2009.

Long-term Toxicology Studies

In September 2008, Anadys initiated long-term, chronic toxicology studies of ANA598, of 26 weeks duration in rats a
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
2. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
3. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
6. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
9. Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells
10. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
11. Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... MISSISSAUGA, ON , Feb. 27, 2015 /CNW/ - Covalon ... advanced medical technologies company, today announced financial results for ... For the three months ended December 31, 2014, ... for the quarter was $229,820 or $0.02 per share.  ... Pedlar , said "I am very pleased with the ...
(Date:2/27/2015)...  Bionik Laboratories Corp. (OTC:DWTPD), a Delaware ... acquired Bionik Laboratories, Inc., a Toronto ... qualified accredited investors of units consisting of its common ... $6.2 million. Shares of the Company,s common stock will ... the symbol "DWTPD" until FINRA,s approval of the ticker ...
(Date:2/26/2015)... DIEGO , Feb. 26, 2015  Tandem Diabetes ... device company and manufacturer of the t:slim® and t:flex™ ... public offering of 5,250,000 shares of its common stock ... share.  The net proceeds to Tandem from this offering ... discounts and commissions and other estimated offering expenses payable ...
Breaking Medicine Technology:Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3Bionik Laboratories Raises $6.2 Million 2Bionik Laboratories Raises $6.2 Million 3Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 3
... Utah, May 3, 2011 Healthcare workers now have the ... take precautions to better protect themselves, and share information and ... BD Medical, a segment of BD (Becton, Dickinson and Company) ... The BD Making Safety Safer(SM) program will provide nurses ...
... GenVec, Inc. (Nasdaq: GNVCD) announced that it will release financial ... Monday, May 9, 2011 after market close.  GenVec will hold ... 10, 2011 to discuss the company,s first quarter financial results ... live conference call, please dial 877-558-0567 (U.S. or Canada) or ...
Cached Medicine Technology:Resource Now Available to Help Clinicians Reduce Risk of Blood Exposure from Short Peripheral IV Catheter Insertion 2Resource Now Available to Help Clinicians Reduce Risk of Blood Exposure from Short Peripheral IV Catheter Insertion 3GenVec to Host First Quarter 2011 Earnings Call and Webcast 2
(Date:2/28/2015)... March 01, 2015 Heart diseases are ... 10 percent of urban adult population and 5 percent ... heart diseases and 20-30 percent of them require specialized ... ailments and coronary vascular diseases (CVD). , A division ... new market research report titled “Indian Coronary Stent Market ...
(Date:2/28/2015)... 28, 2015 The Classic Denture ... a new special. Throughout all of March patients ... , This service can help overall mouth ... pain. Patients may notice certain symptoms that suggest the ... These symptoms include: , 1.    Pain, clicking, and popping in ...
(Date:2/28/2015)... 28, 2015 A study out of ... gene therapy procedure for the treatment of a hereditary ... Authored by Dr. Robert MacLaren, professor of ... the Lancet Medical Journal on January 16, 2014 , ... rare genetic disorder that mostly affects men and leads ...
(Date:2/28/2015)... Beach, CA (PRWEB) February 28, 2015 ... needs of Central Coast area residents, recently announced a ... System. It’s a treatment option for new and ... kick off 2015 with a bright, white smile, Dr. ... discounted price of $299, marked down from the regular ...
(Date:2/28/2015)... 28, 2015 On Thursday, February 26th, Forbes ... Easy For Scammers To Steal Your Data , which stresses ... hands on a DIY phishing kit, or any kind of ... on another important point about how everyone’s cyber security is ... implemented, “like compromising legitimate content management systems or blogs in ...
Breaking Medicine News(10 mins):Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 2Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 3Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 4
... and more complications later, studies find , , MONDAY, Oct. ... arthritis face twice the risk of a heart attack, ... to have more heart-related complications, new research says. ... which causes the lower chambers of the heart to ...
... written and verbal instructions on the proper way to ... to suffer the serious gastrointestinal and brain bleeding problems ... to new research from the University of Pennsylvania School ... Journal of General Internal Medicine , also shows ...
... Mo. The blood circulates through the body ... beginning to understand. Now, University of Missouri researcher ... and Blood Institute,s prestigious Method to Extend Research ... defining the signaling processes that control blood flow ...
... SpectraCell Laboratories, Inc.,announced that it has doubled ... a 20,000 sq. ft. building that was ... expansion added a second freestanding 20,000 sq.,ft. ... $3.5 million facility houses,SpectraCell,s state-of-the-art clinical laboratory ...
... offer ,Stem Cells 102, to present facts to ... issues surrounding the,safety and benefits of stem cell ... University of,Michigan experts are providing educational information to ... federal and state,oversight that apply to all human ...
... 27 The HealthCentral,Network, Inc. (http://www.HealthCentral.com ) ... business development for HealthCentral, has been,named President and ... a proven track record of growing young businesses, ... be responsible for,audience growth, user engagement, and revenue, ...
Cached Medicine News:Health News:Rheumatoid Arthritis a Threat to the Heart 2Health News:Rheumatoid Arthritis a Threat to the Heart 3Health News:Rheumatoid Arthritis a Threat to the Heart 4Health News:Better instructions reduce complications among patients using common blood thinner 2Health News:Better instructions reduce complications among patients using common blood thinner 3Health News:Researcher to provide new insight for treating vascular disease 2Health News:SpectraCell Laboratories Expands Operations in New Facility 2Health News:The Truth About Stem Cell Science 2Health News:The Truth About Stem Cell Science 3Health News:The Truth About Stem Cell Science 4Health News:The HealthCentral Network Names Jeremy Shane President and Chief Operating Officer 2Health News:The HealthCentral Network Names Jeremy Shane President and Chief Operating Officer 3
1.0 mm diameter head, 0.75 mm deep bite....
Optec vision tester....
... standardized glare testing. It can be used with ... evaluation of glare disability. For cataract documentation, the ... two on-coming halogen car headlights as seen at ... be adjusted to simulate other glare conditions, as ...
Designed to determine the precise length of limbal incisions and proper alignment of closing sutures. Curved marking blade with 2 mm lines spaced 1 mm apart-measures up to 10 mm. Round knurled handle...
Medicine Products: